Isomorphic Labs, the AI drug discovery company under Alphabet, announced on November 17, 2026 that it had raised $5 billion in a Series C round (announcement). In its Series B in May, the company set a goal of advancing its drug candidates into clinical trials and said it would use funds to hire clinical development staff. According to the latest announcement, it is seeing favorable preclinical results in its own research programs in cancer and immune diseases, as well as in its collaborations with pharmaceutical companies. The new funds will go toward improving its drug discovery AI and developing drug candidates, and will continue to support the build-out of its clinical development and translational research capabilities.
$7.1 billion raised in six months, with clinical development buildout accelerating
Isomorphic Labs first raised outside capital on March 31, 2025, securing $600 million. In May 2026, it raised $2.1 billion in a Series B led by Thrive Capital, and the Series C was co-led by Greenoaks and Sequoia Capital. New investors including Andreessen Horowitz (a16z) joined the round, and Alphabet also invested additional funds. Existing investors such as Thrive Capital and the UK's Sovereign AI Fund also participated.
Combined, the May and November rounds bring the company's two 2026 financings to $7.1 billion. For both rounds, the main stated uses of funds are developing the company's proprietary AI drug design system, IsoDDE (Isomorphic Labs Drug Design Engine), and expanding drug discovery programs, both its own and those with partners.
| Announcement date | Round | Amount raised | Main use of funds |
|---|---|---|---|
| May 12, 2026 | Series B | $2.1 billion | Developing IsoDDE, advancing drug candidates into clinical trials, hiring clinical staff at each site |
| November 17, 2026 | Series C | $5 billion | Improving IsoDDE, expanding in-house and partner drug discovery programs, building out clinical development and translational research capabilities |
Note: Total of the two equity financings announced in 2026, in US dollars ($2.1 billion + $5 billion).
In its Series B announcement in May, the company said it would hire clinical development specialists, in addition to AI researchers and engineers, in order to move drug candidates into clinical trials. The November announcement states that it will continue to invest in building the capabilities needed to expand translational research and clinical development.
Translational research is the work of taking findings from basic and preclinical research and applying them to human clinical studies and the development of treatments. For example, to determine whether a drug's effect confirmed in experiments also occurs in humans, it is necessary to decide what to measure in a clinical trial and which results to evaluate. Isomorphic Labs is seeking to set up a structure that can carry out this work, from research through clinical development, in an integrated way. The company has not disclosed its valuation from this round or how the funds will be allocated among uses.
Up to $2.9 billion in milestone payments from two pharma partnerships
On January 7, 2024, Isomorphic Labs announced drug discovery collaborations with US pharmaceutical giant Eli Lilly and Switzerland's Novartis. The upfront payments disclosed for the two initial agreements total $82.5 million, and milestone payments tied to R&D progress and other factors could reach up to $2.9 billion.
| Partner / source document | Upfront payment | Milestone payment cap |
|---|---|---|
| Eli Lilly (PDF) | $45 million | $1.7 billion |
| Novartis (PDF) | $37.5 million | $1.2 billion |
| Total | $82.5 million | $2.9 billion |
Note: Based on the terms of the two initial agreements announced on January 7, 2024. Excludes separate research funding, royalties on future sales, and consideration for additional agreements.
In these partnerships, upfront payments are made at signing, while milestone payments are made when R&D goals set out in the contracts are achieved. By contrast, the funds raised in the Series C can be used for the company's own drug discovery programs and clinical development infrastructure, separately from milestone payments under partner contracts. The difference is that development can proceed without waiting for income tied to the progress of partnered projects.
The scope of its pharma collaborations is also widening. The initial Novartis agreement covered three drug targets, but in February 2025 the two companies agreed to add up to three further research programs on the same economic terms as the original. In addition, the collaboration with Johnson & Johnson announced in January 2026 covers multiple drug targets and extends the research scope beyond small molecules to biologics such as antibodies.
While expanding joint research with pharmaceutical companies, Isomorphic Labs is also advancing its own drug candidates for cancer and immune diseases. As the number of development projects grows, it will also need a research setup to validate AI-designed compounds experimentally and move promising candidates into preclinical studies and clinical trials.
From AI molecular design to experimental validation
In 2024, Isomorphic Labs and Google DeepMind jointly released AlphaFold 3, which predicts the structures of molecules such as proteins. On February 10, 2026, the company described the capabilities of IsoDDE, an integrated drug discovery system that goes beyond structure prediction, in a technical report.
IsoDDE not only predicts the three-dimensional structure in which a protein and a candidate drug molecule bind, but also estimates the strength of that binding. Structure prediction shows where and in what form a candidate molecule binds to a target protein. Predicting binding affinity then makes it possible to narrow a large pool of potential binders down to the molecules that should be prioritized for experimental validation.
In an explanation on September 29, company President Max Jaderberg described a plan to carry out the entire process in-house, from data generation and preparation through AI molecular design, experimental validation, and clinical development. As a concrete example, he described a case in which AI was used to narrow down promising compounds and experiments then confirmed that a selected molecule acted on its target. The name of the target was not disclosed; what was presented was the result of a specific molecular design and its experimental validation.
The company is also investing in the data that underpins AI predictions. On October 7, it announced its participation in the Virtual Biology Initiative, led by Biohub and others. The initiative builds public data that can be used to study disease mechanisms with AI, and Isomorphic Labs, Google DeepMind, and Meta have said they will contribute a combined $300 million. The amount each company will contribute, and whether Series C funds will go toward the initiative, have not been disclosed.
Indicators to watch for progress toward clinical trials
In its November Series C announcement, Isomorphic Labs said it was seeing favorable preclinical results in its own programs in oncology and immunology and in its pharma collaborations. However, it did not disclose the names of its lead drug candidates, the specific target diseases, or numerical preclinical data. It also did not mention the country where trials would be conducted, start dates, or first dosing in humans.
In the United States, before starting clinical trials of a drug candidate, a developer submits an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), including preclinical results and a clinical trial plan. According to the FDA's guide to clinical research, the Phase 1 trials that follow mainly examine safety and appropriate dosing.
If the names of drug candidates, target diseases, or the start of clinical trials are announced going forward, it will become possible to see which research programs have moved from the preclinical stage to human trials. An announcement of first dosing would be a concrete milestone showing that administration to humans has actually begun. If multiple in-house candidates then enter clinical trials, that would provide material for assessing whether the setup linking AI molecular design, experimental validation, and clinical development works across different research programs.
